Pliant Therapeutics, Inc. (PLRX) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.38
↓-81% vs avg
5yr avg: 2.06
30Y Low0.4·High2.9
ROE
↓
-61.5%
↑-26% vs avg
5yr avg: -49.0%
30Y Low-62%·High-29%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PLRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Pliant Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $70M | $75M | $797M | $1.1B | $812M | $484M | $808M | — | — | — |
| Enterprise Value | $54M | $59M | $786M | $1.0B | $794M | $439M | $757M | — | — | — |
| P/E Ratio → | -0.47 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | 673.04 | 83.86 | 63.91 | 19.32 | — | — | — |
| P/B Ratio | 0.38 | 0.41 | 2.62 | 2.25 | 2.59 | 2.43 | 2.85 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PLRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 640.22 | 82.01 | 58.04 | 18.10 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
PLRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -61.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating Margin | — | — | — | -11654.7% | -1313.4% | -1288.1% | -99.6% | -2.2% | — | — |
| Net Profit Margin | — | — | — | -10211.1% | -1273.3% | -1284.5% | -99.3% | -1.1% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -61.5% | -61.5% | -54.1% | -41.0% | -48.1% | -40.3% | -29.4% | — | -2458.5% | -616.5% |
| ROA | -48.0% | -48.0% | -46.3% | -37.4% | -43.1% | -37.6% | -20.0% | -0.7% | -82.9% | -314.7% |
| ROIC | -49.2% | -49.2% | -47.9% | -38.5% | -42.4% | -37.8% | -42.7% | — | — | — |
| ROCE | -52.4% | -52.4% | -53.9% | -45.4% | -47.9% | -39.9% | -21.1% | -1.4% | -95.4% | -545.3% |
PLRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $45M exceeds total debt of $29M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.20 | 0.02 | 0.05 | 0.04 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.04 | -0.11 | -0.06 | -0.22 | -0.18 | — | — | -1.27 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -58.65 | -58.65 | -68.54 | -126.34 | -154.91 | — | -113.78 | -5.70 | — | — |
Net cash position: cash ($45M) exceeds total debt ($29M)
PLRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Pliant Therapeutics, Inc.'s current ratio of 12.00x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 17.72x to 12.00x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.00 | 12.00 | 10.91 | 17.72 | 14.23 | 12.44 | 25.07 | 13.69 | 12.14 | 1.48 |
| Quick Ratio | 12.00 | 12.00 | 10.91 | 17.72 | 14.23 | 12.44 | 25.07 | 13.69 | 12.14 | 1.48 |
| Cash Ratio | 11.67 | 11.67 | 10.71 | 17.33 | 13.85 | 11.92 | 23.87 | 12.58 | 11.99 | 1.33 |
| Asset Turnover | — | — | — | 0.00 | 0.03 | 0.03 | 0.14 | 0.48 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 692.34 | 118.49 | 118.87 | 81.72 | 47.25 | — | — |
PLRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Pliant Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $61M | $61M | $59M | $42M | $36M | $36M | $36M | $17M | $803497 |
Peer Comparison
Compare PLRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PLRXYou | $70M | -0.5 | — | — | — | — | -61.5% | -49.2% | — |
 GILD | $156B | 18.5 | 12.0 | 16.5 | 78.8% | 39.7% | 40.7% | 23.2% | 1.7 |
 IDYA | $3B | -22.6 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 HALO | $8B | 27.1 | 11.3 | 12.8 | 78.1% | 58.4% | 153.6% | 32.1% | 2.4 |
 AKBA | $248M | -44.4 | 11.3 | 3.6 | 83.3% | 9.9% | -16.4% | 23.2% | 8.7 |
 INVA | $2B | 6.9 | 6.8 | 8.6 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 MDGL | $11B | -37.4 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 HIMS | $6B | 52.6 | 43.2 | 79.6 | 73.8% | 4.5% | 25.2% | 8.6% | 7.9 |
 ARWR | $10B | -6108.2 | 87.0 | 66.9 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 VKTX | $3B | -9.0 | — | — | — | — | -47.3% | -44.4% | — |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
What if you invested $1,000 in PLRX 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in PLRX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs PLRX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationPLRX vs GILD — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Gilead Sciences, Inc..
Compare NowPLRX — Frequently Asked Questions
Quick answers to the most common questions about buying PLRX stock.
What is Pliant Therapeutics, Inc.'s P/E ratio?
Pliant Therapeutics, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
What is Pliant Therapeutics, Inc.'s ROE?
Pliant Therapeutics, Inc.'s return on equity (ROE) is -61.5%. The historical average is -45.8%.
Is PLRX stock overvalued?
Based on historical data, Pliant Therapeutics, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.